Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Hematologic Malignancies

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1665179

Hereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: A case report

Provisionally accepted
Chi-E  QiuChi-E Qiu1*Lei  LeiLei Lei1Guo  JiangGuo Jiang2Xiuqun  HuangXiuqun Huang2Yadan  LiYadan Li1
  • 1Northeast Yunnan Central Hospital, Zhaotong, China
  • 2The First People's Hospital of Zhaotong, zhaotong, China

The final, formatted version of the article will be published soon.

Hereditary spherocytosis (HS) is a genetic hemolytic disorder primarily characterized by hemolytic anemia, jaundice, splenomegaly, and frequent complications, including cholelithiasis, accompanied by the presence of spherocytes in the peripheral blood. This disorder predominantly follows an autosomal dominant inheritance pattern; however, certain cases exhibit an autosomal recessive mode of inheritance. HS is the most prevalent disorder associated with defects in the red blood cell membrane. Primary myelofi-brosis (PMF), a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly resulting from extramedullary hematopoiesis, is associated with the JAK2 V617F mutation. Currently, there are no documented instances of co-occurrence of HS and PMF in the literature. We report the case of a 37-year-old male who experienced recurrent abdominal distension and splenomegaly over the past decade, along with elevated platelet counts over the past nine years. The patient tested positive for the JAK2V617F mutation, and bone marrow smears revealed the presence of teardrop-shaped erythrocytes. Peripheral blood smears indicated the presence of approximately 20% of spherocytes. The morphology of the bone marrow biopsy specimen was consistent with an MPN, classified as MF-2 grade. The highly specific eosin-5'-maleimide binding assay demonstrated a reduced mean fluorescence intensity of 25.73%. The patient was managed with aspirin and ruxolitinib and continued to be monitored through follow-up evaluations.

Keywords: Hereditary spherocytosis, Primary Myelofibrosis, JAK2V617F, Comorbidity, Myeloproliferative neoplasm

Received: 13 Jul 2025; Accepted: 03 Oct 2025.

Copyright: © 2025 Qiu, Lei, Jiang, Huang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Chi-E Qiu, 13508702069@139.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.